That is very interesting. I am wondering if the steep sell off and utter silence from the company is due to AMBS cleaning its books (ie elimination of one or two of its toxic financiers) in order to appease a partner for ESS? In other words, that parner didn't want anything or anyone to compromise ESS again and the terms of some of its funding could have been a liability. Any thoughts on that? Of course, we'll find out more hopefully in January. But it is critical that management come through on something.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links